These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 1535688

  • 21. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B, Angersbach D, Jost WH.
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [Abstract] [Full Text] [Related]

  • 22. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
    Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN.
    Clin Neuropharmacol; 1998 Apr; 21(6):339-43. PubMed ID: 9844789
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S, Factor SA, Molho ES, Feustel PJ.
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP, Boas J.
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [Abstract] [Full Text] [Related]

  • 32. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E, Blesa R, Bayes A, Forcadell F.
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Therapeutic experiences with an abeorphine derivative in Parkinson's disease.
    Birbamer G, Ransmayr G, Gerstenbrand F, Poewe W.
    Adv Neurol; 1987 Apr; 45():591-2. PubMed ID: 3825736
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Multiple dopamine receptors and their implications in medicine.
    Kebabian JW.
    Curr Opin Neurol Neurosurg; 1992 Aug; 5(4):514-8. PubMed ID: 1387567
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.